课题基金 / 基金详情

项目摘要

项目成果

Carl G Maki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Wild-type p53 is a potent tumor suppressor that is activated by DNA damage and other stresses. There has been considerable interest in restoring wild-type p53 function as a therapeutic strategy. This goal has led to the development of the Nutlin-3 (Nutlin), a small molecule that activates wild-type p53 by blocking its interaction with MDM2, the primary negative regulator of p53 activity in cells. Notably, Nutlin activates p53 through a non-genotoxic mechanism, and thus its use as a therapeutic agent may spare tissues of deleterious side-effects associated with common DNA damaging drugs. Effective use of Nutlin requires that its effects on cells be fully understood. We have examined the response of various p53 wild-type cell lines to transient Nutlin treatment. We find that p53 activation by Nutlin can promote growth arrest or apoptosis in cells dependent on activation of survival pathways, and we have identified a candidate survival factor that protects cells from Nutlin-induced apoptosis. We also find that Nutlin has surprising effects on cytoskeletal organization and control of DNA endoreduplication. The purpose of this grant is to determine the effects of Nutlin-mediated p53 activation on these various cellular responses. PUBLIC HEALTH RELEVANCE: Project Narrative: Cell growth can be considered similar to driving a car; there are accelerators that increase cell growth and brakes that prevent cells from growing too fast. The p53 protein is an important cell brake that prevents normal cells from becoming cancer, and p53 is inactive in most human cancers. We are studying the effects of p53 activation by Nutlin-3a, a small molecule that specifically activates wild-type p53 in a subset of cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A synthetic lethal approach for targeting p53 deficient triple negative breast cancer
  • 批准号:
    10650026
  • 项目类别:
  • 资助金额:
    $22.16万
  • 财政年份:
    2023
  • 负责人:
    Carl G Maki
  • 依托单位:
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer
  • 批准号:
    9461165
  • 项目类别:
  • 资助金额:
    $5.69万
  • 财政年份:
    2017
  • 负责人:
    Carl G Maki
  • 依托单位:
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer
  • 批准号:
    9115348
  • 项目类别:
  • 资助金额:
    $35.46万
  • 财政年份:
    2016
  • 负责人:
    Carl G Maki
  • 依托单位:
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer
  • 批准号:
    9253372
  • 项目类别:
  • 资助金额:
    $35.46万
  • 财政年份:
    2016
  • 负责人:
    Carl G Maki
  • 依托单位:
海外基金